Zhejiang Jingxin Pharmaceutical Co., Ltd. (SHE:002020)
China · Delayed Price · Currency is CNY 11.68
-0.18 (-1.52%)
Sep 10, 2026, 3:04 PM CST
SHE:002020 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 9,651 | 15,445 | 11,021 | 10,952 | 10,487 | 8,188 | |
Market Cap Growth | -41.78% | 40.14% | 0.63% | 4.43% | 28.08% | 23.37% |
Enterprise Value | 8,749 | 15,062 | 10,330 | 9,961 | 8,947 | 6,447 |
Last Close Price | 11.86 | 18.45 | 12.11 | 11.73 | 11.02 | 8.31 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 12.90 | 20.38 | 15.48 | 17.70 | 15.84 | 13.37 |
Forward PE | - | 17.99 | 14.75 | 14.91 | 13.98 | 10.14 |
PS Ratio | 2.39 | 3.80 | 2.65 | 2.74 | 2.78 | 2.36 |
PB Ratio | 1.64 | 2.63 | 1.84 | 1.98 | 2.03 | 1.67 |
P/TBV Ratio | 1.91 | 3.05 | 2.10 | 2.30 | 2.40 | 1.88 |
P/FCF Ratio | 15.76 | 26.70 | 23.18 | 40.07 | 30.83 | - |
P/OCF Ratio | 12.06 | 19.77 | 15.18 | 13.81 | 12.26 | 21.93 |
PEG Ratio | - | 0.79 | 0.79 | 0.79 | 0.79 | 0.79 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.17 | 3.70 | 2.48 | 2.49 | 2.37 | 1.86 |
EV/EBITDA Ratio | 8.20 | 14.53 | 10.37 | 12.69 | 11.67 | 9.03 |
EV/EBIT Ratio | 11.09 | 19.57 | 14.46 | 17.20 | 14.58 | 11.16 |
EV/FCF Ratio | 14.29 | 26.04 | 21.72 | 36.45 | 26.30 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.04 |
Debt / EBITDA Ratio | 0.29 | 0.30 | 0.31 | 0.40 | 0.38 | 0.27 |
Debt / FCF Ratio | 0.51 | 0.54 | 0.67 | 1.18 | 0.87 | - |
Net Debt / Equity Ratio | -0.09 | -0.09 | -0.14 | -0.23 | -0.31 | -0.36 |
Net Debt / EBITDA Ratio | -0.51 | -0.52 | -0.83 | -1.64 | -2.11 | -2.51 |
Net Debt / FCF Ratio | -0.87 | -0.93 | -1.74 | -4.72 | -4.76 | 53.62 |
Asset Turnover | - | 0.49 | 0.51 | 0.52 | 0.54 | 0.57 |
Inventory Turnover | - | 2.65 | 2.90 | 2.79 | 2.44 | 2.63 |
Quick Ratio | - | 0.93 | 0.96 | 1.10 | 1.37 | 1.83 |
Current Ratio | - | 1.73 | 1.36 | 1.62 | 1.81 | 2.32 |
Return on Equity (ROE) | 13.24% | 12.92% | 12.46% | 11.64% | 13.26% | 13.99% |
Return on Assets (ROA) | - | 5.80% | 5.42% | 4.72% | 5.52% | 5.91% |
Return on Invested Capital (ROIC) | 13.16% | 13.00% | 12.92% | 13.07% | 16.40% | 19.71% |
Return on Capital Employed (ROCE) | - | 12.40% | 11.30% | 9.80% | 11.10% | 11.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 7.87% | 4.91% | 6.46% | 5.65% | 6.31% | 7.48% |
FCF Yield | 6.35% | 3.74% | 4.32% | 2.50% | 3.24% | -0.41% |
Dividend Yield | 2.77% | 1.90% | 2.89% | 2.56% | 2.72% | 3.61% |
Payout Ratio | 38.06% | 37.58% | 36.28% | 41.74% | 39.04% | 37.90% |
Buyback Yield / Dilution | 2.55% | 3.95% | 0.21% | 0.06% | -5.31% | -2.55% |
Total Shareholder Return | 5.31% | 5.85% | 3.10% | 2.62% | -2.58% | 1.06% |